MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
08 11 2022
08 11 2022
Historique:
accepted:
21
03
2022
received:
01
11
2021
pubmed:
8
4
2022
medline:
3
11
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Monoclonal gammopathy of undetermined significance (MGUS) and clonal hematopoiesis (CH) are 2 preclinical clonal expansions of hematopoietic cells whose prevalence rises with age, reaching almost 10% in people of aged 70 years and older. The increased risk of myeloid malignancies in patients with myeloma is well defined, and the study of the association between CH and MGUS could help explain this phenomenon. Here, we analyzed a fully clinically annotated dataset of 777 older subjects (median age, 91 years) previously screened for prevalence of CH. The prevalence of MGUS and CH was 9.6% and 17.3%, respectively. We detected CH in 9.7% of the patients with MGUS and MGUS in 5.5% of the patients with CH. We did not find a significant correlation between the presence of MGUS and CH. Furthermore, the 2 conditions showed a differential association with clinical and laboratory covariates, suggesting that MGUS and CH may represent age-associated unrelated clonal drifts of hematopoietic cells. Confirmatory studies are needed to assess the relevance of CH in plasma cell disorders. This trial was registered at www.clinicaltrials.gov as #NCT03907553.
Identifiants
pubmed: 35390146
pii: 484635
doi: 10.1182/bloodadvances.2021006498
pmc: PMC9618778
doi:
Banques de données
ClinicalTrials.gov
['NCT03907553']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5702-5706Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Nat Med. 2021 Nov;27(11):1921-1927
pubmed: 34663986
Leuk Res Rep. 2020 Apr 23;13:100202
pubmed: 32373459
Blood. 2017 Aug 10;130(6):742-752
pubmed: 28483762
Blood. 2011 Oct 13;118(15):4086-92
pubmed: 21795746
Blood Adv. 2022 Apr 12;6(7):2230-2235
pubmed: 34847227
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
Nat Commun. 2021 Mar 25;12(1):1861
pubmed: 33767199
Alzheimers Dement. 2015 Mar;11(3):258-70.e3
pubmed: 25150732
Blood. 2021 Nov 4;138(18):1727-1732
pubmed: 34139005
Nature. 2020 Feb;578(7794):266-272
pubmed: 31996850
Lancet Haematol. 2017 Sep;4(9):e431-e442
pubmed: 28826616
Cell Rep. 2015 Mar 3;10(8):1239-45
pubmed: 25732814
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Blood. 2021 Mar 4;137(9):1260-1263
pubmed: 33120432
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
Nat Commun. 2020 Jun 12;11(1):2996
pubmed: 32533060
JAMA Oncol. 2019 Sep 01;5(9):1293-1301
pubmed: 31318385
Am J Med. 1978 May;64(5):814-26
pubmed: 645746
Blood. 2021 Nov 25;138(21):2093-2105
pubmed: 34125889